Drug Profile

Fomepizole

Alternative Names: 4-MP; Antizol; Fomepizole; Fomepizole Intravenous Infusion 1.5g "Takeda"

Latest Information Update: 27 Apr 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Nonindustrial source
Developer AFT Pharmaceuticals; Endo, Inc.; Jazz Pharmaceuticals plc; Takeda
Class Antidotes; Pyrazoles; Small molecules
Mechanism of Action Alcohol dehydrogenase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Methanol poisoning; Ethylene glycol poisoning
New Molecular Entity Yes

Highest Development Phases

Marketed Ethylene glycol poisoning; Methanol poisoning

Most Recent Events

23 Apr 2024 Endo International has been acquired and merged into Endo, Inc.
24 Apr 2017 Launched for Ethylene Glycol poisoning in Australia (IV)
24 Apr 2017 Launched for Methanol poisoning in Australia (IV)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com